Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate - Candlesense
AVZO Clinical trials

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

(AVZO) SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics Announces FDA Clearance of IND Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific ADC

Related Questions

What are the anticipated clinical trial timelines and key milestones for AVZO-103 following IND clearance? How does AVZO-103’s Nectin4/TROP2 bispecific ADC compare to existing ADCs and competitors in terms of efficacy, safety, and market positioning? What potential revenue uplift and valuation impact could successful development of AVZO-103 have on AVZO’s stock price?
Find similar articles on Candlesense businesswire